

Hold (Buy) EUR 9.50 (EUR 8.50) Price EUR 8.20 Upside 15.9 %	Value Indicators: EUR DCF: 9.46 FCF-Value Potential: 10.19	Share data: Bloomberg: M3V GR Reuters: M3VG ISIN: DE000A0LBFE4	Description: A leading supplier of software for visual-based medical equipment
	Market Snapshot: EUR m Market cap: 14.9 No. of shares (m): 1.8 EV: 10.0 Freefloat MC: 2.5 Ø Trad. Vol. (30d): 7.20 th	Shareholders: Freefloat 16.7 % Others 22.6 % Professor Dr. Heinz-Otto 19.5 % Dr. Carl J. G. Evertsz 19.5 % Dr. Hartmut Jürgens 16.5 %	Risk Profile (WRe): 2012e Beta: 1.9 Price / Book: 0.7 x Equity Ratio: 71 % Net Fin. Debt / EBITDA: -0.9 x Net Debt / EBITDA: -0.9 x

Costs reduced; Revenue stabilised

Stated Figures Q3/2012:									
FY End: 31.12. in EUR m	Q3 2012	Q3 2012e	Q3 2011	yoy	9M 2012	9M 2012e	9M 2011	yoy	
Sales	3.2	3.2	3.4	-5 %	10.1	10.1	10.1	0 %	
EBIT	0.7	0.5	0.5	44 %	2.0	1.7	0.7	194 %	
Margin	21.5 %	14.3 %	14.1 %		19.3 %	17.0 %	6.6 %		
Net income	-0.2	0.2	0.2	n.a.	0.5	0.9	-0.9	n.a.	
Margin	-6.1 %	7.8 %	7.3 %		4.6 %	9.1 %	-9.1 %		
EPS	-0.12	0.15	0.15	n.a.	0.27	0.53	-0.54	n.a.	

Comment on Figures:


- In the first nine months, the company managed to stabilise revenues.
- EBIT of EUR 2m in the first nine months already almost reaches WRe full year forecast.
- Net result is distorted by provisions and deferred taxes (IFRS) and is no longer relevant for consideration in our assessment.

Mevis Medical Solutions AG published earnings figures for the third quarter and first nine months of the year, during the German Equity Forum on November 12. While revenues were in line with expectations, the company successfully managed to **increase operating earnings through strict cost discipline**. Personnel costs (-14%) and other operating expenses (-20%) both clearly declined from the comparable year-earlier period. The reorganisation of the executive board, the successful closing of the Japanese business and the shutting down of the US subsidiary at the end of the year, mark particular milestones of the comprehensive restructuring programme. In summary, the earnings increase is therefore predominantly a result of a reduction in costs. **The revenue was held constant in the first nine months**, which meant that, as well as the cost reduction, the second target was also achieved. Development in both segments, Digital Mammography (-1%) and Other Diagnostics (+4%), was stable. However Digital Mammography with 76% of revenue still accounts for the most important part of company revenues. A significant risk, the long-term reduction in these revenues due to the already very high penetration of the target market, remains. The gain of new industry customers, the targeted expansion of the product portfolio as well as the expansion of the services business should serve to counteract this risk. The target of stabilising the revenue in the medium term is however, owing to the above-mentioned imbalance in the division of revenues, very demanding. The estimates (WR) still anticipate a slight decrease in revenues for the coming years while the very successful cost saving measures mean the earnings forecasts are being raised. Based on the new forecasts the price target increases from EUR 9.50 (8.50). **As the share price potential on the current level however has almost been exhausted, the share is now being downgraded to Hold from Buy.**

Changes in Estimates:						
FY End: 31.12. in EUR m	2012e (old)	+ / -	2013e (old)	+ / -	2014e (old)	+ / -
Sales	13.7	0.0 %	13.5	0.0 %	13.0	0.0 %
EBITDA	5.5	4.3 %	5.2	7.7 %	4.7	9.7 %
EBIT	2.2	13.8 %	2.0	23.5 %	1.7	22.8 %
EBT	2.1	14.4 %	2.1	22.4 %	1.8	21.6 %
Net income	1.1	-41.2 %	1.4	22.4 %	1.2	21.6 %

Comment on Changes:


- Further earnings potential for next year, 2013, as implemented cost-saving measures will be fully effective for the first time.
- Long-term stabilisation of revenues remains however a demanding target.
- The change in the net result is based on tax-related special items (IFRS) and is not relevant for our assessment/valuation.




Rel. Performance vs CDAX:	
1 month:	-2.6 %
6 months:	36.8 %
Year to date:	96.6 %
Trailing 12 months:	177.2 %

Company events:


FY End: 31.12. in EUR m	CAGR (11-14e)	2008	2009	2010	2011	2012e	2013e	2014e
Sales	-1.7 %	10.8	13.9	14.3	13.7	13.7	13.5	13.0
Change Sales yoy		37.4 %	27.9 %	3.0 %	-4.3 %	0.2 %	-1.5 %	-3.7 %
Gross profit margin		114.5 %	113.3 %	114.7 %	112.3 %	113.5 %	112.3 %	111.4 %
EBITDA	5.5 %	1.8	4.5	3.5	4.4	5.7	5.6	5.2
Margin		16.2 %	32.3 %	24.2 %	32.3 %	41.9 %	41.8 %	39.8 %
EBIT	-	0.7	1.6	-5.4	-1.6	2.5	2.5	2.1
Margin		6.1 %	11.8 %	-38.0 %	-12.0 %	18.4 %	18.3 %	16.3 %
Net income	-	2.1	0.4	-8.3	-4.1	0.6	1.7	1.4
EPS	-	1.21	0.23	-4.89	-2.38	0.36	0.97	0.84
EPS adj.	-	1.21	0.23	-4.89	-2.38	0.36	0.97	0.84
DPS	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield		0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
FCFPS		-0.64	0.02	1.04	1.34	1.27	1.73	1.36
EV / Sales		5.0 x	2.9 x	2.2 x	0.7 x	0.7 x	0.5 x	0.4 x
EV / EBITDA		31.0 x	9.0 x	9.3 x	2.2 x	1.7 x	1.2 x	0.9 x
EV / EBIT		81.9 x	24.7 x	n.a.	n.a.	3.9 x	2.8 x	2.2 x
P / E		26.2 x	102.1 x	n.a.	n.a.	22.8 x	8.5 x	9.8 x
P / E adj.		26.2 x	102.1 x	n.a.	n.a.	22.8 x	8.5 x	9.8 x
FCF Yield Potential		-3.1 %	1.9 %	-7.7 %	3.2 %	16.5 %	33.6 %	43.2 %
Net Debt		-0.8	-0.6	-0.7	-2.8	-5.0	-7.9	-10.3
ROE		6.7 %	1.2 %	-29.1 %	-18.0 %	2.9 %	7.3 %	5.8 %
ROCE (NOPAT)		2.8 %	1.7 %	-28.8 %	-11.0 %	3.7 %	9.7 %	8.7 %
Guidance:	Stable revenues, growing earnings							

Sales development
in EUR m


Source: Warburg Research

Sales by types
2011; in %


Source: Warburg Research

EBIT development
in EUR m



Source: Warburg Research

Company Background


- The origin of MeVis Medical Solutions AG, which was set up in 1998, dates back to 1992, when the CeVis (Center for Complex Systems and Visualization) was founded at the University of Bremen.
- The public company was founded with the aim of developing commercially successful disease-oriented products based on successes in scientific research and to market these.
- Since its foundation, MeVis has been active in the area of computer-aided, image-based medical diagnostics and therapy.
- MeVis has successfully risen to become a globally-leading provider of software solutions for medical imaging. This development is mainly based on the success in the area of digital mammography.
- Together with products by Hologic and Siemens, MeVis's solutions dominate this segment today. Furthermore, MeVis has a broad portfolio of new products.

Competitive Quality


- MeVis follows a strategy of early market presence in the new areas of image-based medical technology. In focus here are mass market products.
- The ability to be an early market entrant differentiates MeVis from competitors.
- MeVis maintains long-term and interdisciplinary cooperation agreements with more than 100 hospitals and leading R&D centres in Germany, Europe, the US and Asia.
- MeVis fosters partnerships with the globally leading medical technology OEMs, for instance Siemens and Hologic.

EBT development
in EUR m


Source: Warburg Research

Sales by segments
2011; in %


Source: Warburg Research

Net income development
in EUR m


Source: Warburg Research

DCF model

Figures in EUR m	Detailed forecast period			Transitional period										Term. Value
	2012e	2013e	2014e	2015e	2016e	2017e	2018e	2019e	2020e	2021e	2022e	2023e	2024e	
Sales	13.7	13.5	13.0	13.0	13.0	13.0	13.0	13.0	13.4	13.8	14.2	14.6	15.1	0.0 %
Sales change	0.2 %	-1.5 %	-3.7 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	
EBIT	2.5	2.5	2.1	2.1	2.1	2.0	2.0	2.0	2.0	2.1	2.1	2.2	2.3	15.0 %
EBIT-margin	18.4 %	18.3 %	16.3 %	16.0 %	16.0 %	15.0 %	15.0 %	15.0 %	15.0 %	15.0 %	15.0 %	15.0 %	15.0 %	
Tax rate (EBT)	74.3 %	35.0 %	35.0 %	35.0 %	35.0 %	35.0 %	35.0 %	35.0 %	35.0 %	35.0 %	35.0 %	35.0 %	35.0 %	15.0 %
NOPAT	0.6	1.6	1.4	1.4	1.4	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.5	
Depreciation	3.2	3.2	3.1	2.9	2.9	2.7	2.6	2.5	2.4	2.3	2.3	2.2	2.1	14.0 %
in % of Sales	23.5 %	23.5 %	23.5 %	22.0 %	22.0 %	21.0 %	20.0 %	19.0 %	18.0 %	17.0 %	16.0 %	15.0 %	14.0 %	
Changes in provisions	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	14.0 %
Change in Liquidity from														
- Working Capital	-0.9	-0.7	-0.4	-0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	14.0 %
- Capex	3.1	3.1	3.1	2.7	2.7	2.7	2.6	2.5	2.4	2.3	2.3	2.2	2.1	
Capex in % of Sales	22.4 %	22.7 %	23.5 %	21.0 %	21.0 %	21.0 %	20.0 %	19.0 %	18.0 %	17.0 %	16.0 %	15.0 %	14.0 %	14.0 %
Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Free Cash Flow (WACC Model)	1.7	2.4	1.8	1.7	1.5	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1
PV of FCF	1.7	2.1	1.4	1.2	0.9	0.7	0.6	0.6	0.5	0.5	0.4	0.4	0.4	
share of PVs	36.15 %			42.69 %										21.16 %

Model parameter

Derivation of WACC:

Debt ratio	15.00 %
Cost of debt	4.2 %
Market return	9.00 %
Risk free rate	4.00 %

WACC 12.10 %

Derivation of Beta:

Financial Strength	1.50
Liquidity	2.00
Cyclicality	2.00
Transparency	2.00
Others	2.00

Beta 1.90**Valuation (m)**

Present values 2024e

Terminal Value	11
Financial liabilities	3
Pension liabilities	5
Hybrid capital	0
Minority interest	0
Market val. of investments	0
Liquidity	8
Equity Value	17
No. of shares (m)	1.8
Value per share (EUR)	9.46

Sensitivity Value per Share (EUR)

Terminal Growth								Delta EBIT-margin							
Beta (WACC)	-0.75 %	-0.50 %	-0.25 %	0.00 %	0.25 %	0.50 %	0.75 %	Beta (WACC)	-1.5 pp	-1.0 pp	-0.5 pp	0.0	+0.5 pp	+1.0 pp	+1.5 pp
2.14 (13.1 %)	8.89	8.91	8.93	8.96	8.99	9.02	9.05	2.14 (13.1 %)	8.38	8.57	8.77	8.96	9.16	9.35	9.55
2.02 (12.6 %)	9.12	9.14	9.17	9.20	9.23	9.26	9.30	2.02 (12.6 %)	8.59	8.80	9.00	9.20	9.40	9.61	9.81
1.96 (12.4 %)	9.24	9.27	9.30	9.33	9.36	9.40	9.43	1.96 (12.4 %)	8.71	8.91	9.12	9.33	9.54	9.74	9.95
1.90 (12.1 %)	9.36	9.39	9.43	9.46	9.50	9.53	9.57	1.90 (12.1 %)	8.83	9.04	9.25	9.46	9.67	9.88	10.09
1.84 (11.9 %)	9.49	9.53	9.56	9.60	9.64	9.68	9.72	1.84 (11.9 %)	8.95	9.17	9.38	9.60	9.82	10.03	10.25
1.78 (11.6 %)	9.63	9.67	9.70	9.74	9.78	9.83	9.87	1.78 (11.6 %)	9.08	9.30	9.52	9.74	9.96	10.18	10.41
1.66 (11.1 %)	9.92	9.96	10.01	10.05	10.10	10.15	10.20	1.66 (11.1 %)	9.36	9.59	9.82	10.05	10.28	10.51	10.74

Free Cash Flow Value Potential

Warburg Research's valuation tool "FCF Value Potential" reflects the ability of the company to generate sustainable free cash flows. It is based on the "FCF potential" - a FCF "ex growth" figure - which assumes unchanged working capital and pure maintenance capex. A value indication is derived by discounting the "FCF potential" of a given year with the weighted costs of capital. The fluctuating value indications over time add a timing element to the DCF model (our preferred valuation tool).

in EUR m	2008	2009	2010	2011	2012e	2013e	2014e
Net Income before minorities	2.1	0.4	-8.3	-4.1	0.6	1.7	1.4
+ Depreciation + Amortisation	1.1	2.8	8.9	6.1	3.2	3.2	3.1
- Net Interest Income	2.0	-0.5	-0.2	-1.3	-0.1	0.1	0.1
- Maintenance Capex	2.8	2.9	3.2	2.9	2.9	3.0	3.0
+ Other	0.0	0.0	0.0	0.0	0.6	0.6	0.6
= Free Cash Flow Potential	-1.7	0.8	-2.5	0.3	1.6	2.3	2.0
Free Cash Flow Yield Potential	-3.1 %	1.9 %	-7.7 %	3.2 %	16.5 %	33.6 %	43.2 %
WACC	12.10 %	12.10 %	12.10 %	12.10 %	12.10 %	12.10 %	12.10 %
= Enterprise Value (EV)	54.5	40.3	32.1	9.6	10.0	7.0	4.6
= Fair Enterprise Value	n.a.	6.3	n.a.	2.6	13.6	19.4	16.5
- Net Debt (Cash)	-2.8	-2.8	-2.8	-2.8	-5.0	-7.9	-10.3
- Pension Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0
- Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0
- Market value of minorities	0.0	0.0	0.0	0.0	0.0	0.0	0.0
+ Market value of investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0
= Fair Market Capitalisation	n.a.	9.1	n.a.	5.4	18.5	27.3	26.8
No. of shares (total) (m)	1.8	1.8	1.8	1.8	1.8	1.8	1.8
= Fair value per share (EUR)	n.a.	5.01	n.a.	2.95	10.19	15.00	14.74
premium (-) / discount (+) in %					24.2 %	82.9 %	79.7 %
Sensitivity Fair value per Share (EUR)							
WACC	15.10 %	n.a.	4.32	n.a.	2.67	8.71	12.93
	14.10 %	n.a.	4.52	n.a.	2.75	9.13	13.45
	13.10 %	n.a.	4.75	n.a.	2.84	9.62	14.04
	12.10 %	n.a.	5.01	n.a.	2.95	10.19	14.74
	11.10 %	n.a.	5.33	n.a.	3.08	10.86	15.55
	10.10 %	n.a.	5.70	n.a.	3.23	11.66	16.53
	9.10 %	n.a.	6.16	n.a.	3.41	12.64	17.73

Valuation							
	2008	2009	2010	2011	2012e	2013e	2014e
Price / Book	1.7 x	1.3 x	1.3 x	0.6 x	0.7 x	0.6 x	0.6 x
Book value per share ex intangibles	3.29	3.17	1.63	1.05	1.63	2.79	3.77
EV / Sales	5.0 x	2.9 x	2.2 x	0.7 x	0.7 x	0.5 x	0.4 x
EV / EBITDA	31.0 x	9.0 x	9.3 x	2.2 x	1.7 x	1.2 x	0.9 x
EV / EBIT	81.9 x	24.7 x	n.a.	n.a.	3.9 x	2.8 x	2.2 x
EV / EBIT adj.*	81.9 x	24.7 x	n.a.	n.a.	3.9 x	2.8 x	2.2 x
P / FCF	n.a.	n.a.	18.5 x	5.4 x	6.5 x	4.7 x	6.0 x
P / E	26.2 x	102.1 x	n.a.	n.a.	22.8 x	8.5 x	9.8 x
P / E adj.*	26.2 x	102.1 x	n.a.	n.a.	22.8 x	8.5 x	9.8 x
Dividend Yield	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Free Cash Flow Yield Potential	-3.1 %	1.9 %	-7.7 %	3.2 %	16.5 %	33.6 %	43.2 %
*Adjustments made for: -							

Consolidated profit & loss

In EUR m	2008	2009	2010	2011	2012e	2013e	2014e
Sales	10.8	13.9	14.3	13.7	13.7	13.5	13.0
Change Sales yoy	37.4 %	27.9 %	3.0 %	-4.3 %	0.2 %	-1.5 %	-3.7 %
Increase / decrease in inventory	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Own work capitalised	1.9	2.3	2.8	2.4	2.4	2.2	2.0
Total Sales	12.8	16.2	17.1	16.1	16.1	15.7	15.0
Material Expenses	0.4	0.5	0.7	0.7	0.5	0.5	0.5
Gross profit	12.4	15.7	16.4	15.4	15.5	15.2	14.5
Gross profit margin	114.5 %	113.3 %	114.7 %	112.3 %	113.5 %	112.3 %	111.4 %
Personnel expenses	7.7	9.8	10.4	9.2	8.3	8.1	8.0
Other operating income	1.1	1.8	1.1	1.1	0.7	0.7	0.7
Other operating expenses	4.1	3.3	3.7	2.9	2.2	2.1	2.0
Unfrequent items	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	1.8	4.5	3.5	4.4	5.7	5.6	5.2
Margin	16.2 %	32.3 %	24.2 %	32.3 %	41.9 %	41.8 %	39.8 %
Depreciation of fixed assets	0.4	0.5	5.8	3.0	0.5	0.5	0.5
EBITA	1.4	3.9	-2.3	1.5	5.2	5.1	4.7
Amortisation of intangible assets	0.7	2.3	3.1	3.1	2.7	2.6	2.5
Goodwill amortization	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	0.7	1.6	-5.4	-1.6	2.5	2.5	2.1
Margin	6.1 %	11.8 %	-38.0 %	-12.0 %	18.4 %	18.3 %	16.3 %
EBIT adj.	0.7	1.6	-5.4	-1.6	2.5	2.5	2.1
Interest income	1.1	0.6	0.4	0.1	0.1	0.1	0.1
Interest expenses	0.3	1.0	0.7	0.3	0.2	0.0	0.0
Other financial income (loss)	1.3	-0.1	0.1	-1.0	0.0	0.0	0.0
EBT	2.7	1.2	-5.6	-2.9	2.4	2.6	2.2
Margin	25.0 %	8.4 %	-39.2 %	-21.3 %	17.7 %	19.0 %	17.1 %
Total taxes	0.6	0.8	2.7	1.2	1.8	0.9	0.8
Net income from continuing operations	2.1	0.4	-8.3	-4.1	0.6	1.7	1.4
Income from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income before minorities	2.1	0.4	-8.3	-4.1	0.6	1.7	1.4
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	2.1	0.4	-8.3	-4.1	0.6	1.7	1.4
Margin	19.5 %	2.9 %	-58.4 %	-29.9 %	4.5 %	12.4 %	11.1 %
Number of shares, average	1.7	1.7	1.7	1.7	1.7	1.7	1.7
EPS	1.21	0.23	-4.89	-2.38	0.36	0.97	0.84
EPS adj.	1.21	0.23	-4.89	-2.38	0.36	0.97	0.84

*Adjustments made for:


Guidance: Stable revenues, growing earnings

Financial Ratios

	2008	2009	2010	2011	2012e	2013e	2014e
Total Operating Costs / Sales	101.7 %	84.4 %	95.3 %	85.2 %	75.6 %	74.5 %	75.5 %
Operating Leverage	0.9 x	5.2 x	n.a.	16.3 x	n.a.	1.4 x	3.8 x
EBITDA / Interest expenses	5.5 x	4.5 x	4.8 x	12.8 x	28.7 x	n.a.	n.a.
Tax rate (EBT)	21.9 %	65.9 %	-48.9 %	-40.4 %	74.3 %	35.0 %	35.0 %
Dividend Payout Ratio	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Sales per Employee	59,912	58,029	63,799	73,935	67,322	60,308	52,795


Sales, EBITDA

in EUR m




Operating Performance

in %



Performance per Share



Source: Warburg Research

Source: Warburg Research



Source: Warburg Research

Consolidated balance sheet

In EUR m	2008	2009	2010	2011	2012e	2013e	2014e
Assets							
Goodwill and other intangible assets	26.9	27.1	22.0	18.9	19.0	19.2	19.5
thereof other intangible assets	10.1	10.5	9.4	6.3	6.4	6.6	6.8
thereof Goodwill	16.7	16.6	12.6	12.6	12.6	12.6	12.6
Property, plant and equipment	1.4	1.2	0.9	0.7	0.4	0.1	-0.1
Financial assets	0.0	0.0	1.3	0.3	0.3	0.3	0.3
Other long-term assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Fixed assets	28.3	28.3	24.2	19.9	19.7	19.6	19.6
Inventories	0.2	0.1	0.1	0.3	0.1	0.1	0.1
Accounts receivable	2.3	4.2	5.1	4.4	3.8	3.3	2.8
Liquid assets	20.3	15.1	8.2	7.5	6.7	9.7	12.0
Other short-term assets	8.5	3.2	1.2	0.5	0.5	0.5	0.5
Current assets	31.3	22.7	14.6	12.7	11.1	13.5	15.4
Total Assets	59.6	51.0	38.8	32.5	30.8	33.2	35.0
Liabilities and shareholders' equity							
Subscribed capital	1.8	1.8	1.8	1.8	1.8	1.8	1.8
Capital reserve	28.4	28.5	28.5	28.1	28.1	28.1	28.1
Retained earnings	0.0	0.0	0.0	0.0	0.6	2.3	3.7
Other equity components	2.4	2.3	-5.5	-9.2	-8.7	-8.2	-7.7
Shareholder's equity	32.6	32.6	24.8	20.7	21.9	24.0	26.0
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total equity	32.6	32.6	24.8	20.7	21.9	24.0	26.0
Provisions	0.2	0.2	1.1	1.1	1.1	1.1	1.1
thereof provisions for pensions and similar obligations	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Financial liabilities (total)	19.4	14.5	7.5	4.7	1.7	1.7	1.7
thereof short-term financial liabilities	0.5	0.4	0.0	0.0	0.0	0.0	0.0
Accounts payable	1.0	1.1	1.3	1.2	1.3	1.5	1.4
Other liabilities	6.3	2.6	4.2	4.8	4.8	4.8	4.8
Liabilities	27.0	18.3	14.0	11.8	9.0	9.2	9.1
Total liabilities and shareholders' equity	59.6	51.0	38.8	32.5	30.8	33.2	35.0

Financial Ratios

	2008	2009	2010	2011	2012e	2013e	2014e
Efficiency of Capital Employment							
Operating Assets Turnover	3.8 x	3.1 x	3.0 x	3.3 x	4.5 x	6.6 x	9.4 x
Capital Employed Turnover	0.3 x	0.4 x	0.6 x	0.8 x	0.8 x	0.8 x	0.8 x
ROA	7.5 %	1.4 %	-34.5 %	-20.6 %	3.2 %	8.5 %	7.4 %
Return on Capital							
ROCE (NOPAT)	2.8 %	1.7 %	-28.8 %	-11.0 %	3.7 %	9.7 %	8.7 %
ROE	6.7 %	1.2 %	-29.1 %	-18.0 %	2.9 %	7.3 %	5.8 %
Adj. ROE	6.7 %	1.2 %	-29.1 %	-18.0 %	2.9 %	7.3 %	5.8 %
Balance sheet quality							
Net Debt	-0.8	-0.6	-0.7	-2.8	-5.0	-7.9	-10.3
Net Financial Debt	-0.8	-0.6	-0.7	-2.8	-5.0	-7.9	-10.3
Net Gearing	-2.4 %	-1.9 %	-2.8 %	-13.5 %	-22.8 %	-33.1 %	-39.6 %
Net Fin. Debt / EBITDA	-46.6 %	-13.8 %	-20.4 %	-63.3 %	-86.6 %	-140.8 %	-198.6 %
Book Value / Share	18.7	18.7	14.5	12.0	12.7	14.0	15.1
Book value per share ex intangibles	3.3	3.2	1.6	1.1	1.6	2.8	3.8

ROCE Development**Net debt in EUR m****Book Value per Share in EUR**

Source: Warburg Research

Source: Warburg Research




Source: Warburg Research

Consolidated cash flow statement

In EUR m	2008	2009	2010	2011	2012e	2013e	2014e
Net income	0.6	-0.2	-5.3	-1.3	0.6	1.7	1.4
Depreciation of fixed assets	0.4	0.5	5.8	3.0	0.5	0.5	0.5
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	0.7	2.3	3.1	3.1	2.7	2.6	2.5
Increase/decrease in long-term provisions	0.2	0.1	0.9	0.0	0.0	0.0	0.0
Other non-cash income and expenses	1.4	0.1	-0.4	0.0	0.0	0.0	0.0
Cash Flow	3.2	2.8	4.0	4.8	3.8	4.8	4.5
Increase / decrease in inventory	-0.1	0.0	0.0	-0.2	0.2	0.0	0.0
Increase / decrease in accounts receivable	-0.6	1.9	-0.5	1.0	0.6	0.5	0.5
Increase / decrease in accounts payable	0.4	-1.6	1.4	-0.5	0.1	0.2	-0.1
Increase / decrease in other working capital positions	0.0	0.0	0.0	0.0	0.5	0.5	0.5
Increase / decrease in working capital (total)	-0.3	0.3	0.9	0.4	1.4	1.2	0.9
Net cash provided by operating activities	2.9	3.1	5.0	5.1	5.3	6.0	5.4
Investments in intangible assets	-2.6	-2.7	-3.0	-2.7	-2.8	-2.8	-2.8
Investments in property, plant and equipment	-1.4	-0.3	-0.2	-0.1	-0.3	-0.3	-0.3
Payments for acquisitions	-4.5	-4.7	-7.2	-3.0	-3.0	0.0	0.0
Financial investments	-5.0	-2.3	3.9	1.1	0.0	0.0	0.0
Income from asset disposals	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net cash provided by investing activities	-13.5	-10.0	-6.5	-4.7	-6.1	-3.1	-3.1
Change in financial liabilities	-0.4	-0.1	-0.4	0.0	-3.0	0.0	0.0
Dividends paid	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Purchase of own shares	-2.2	-0.5	0.0	0.0	0.0	0.0	0.0
Capital measures	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	0.0	0.0	0.0	0.0	3.0	0.0	0.0
Net cash provided by financing activities	-2.6	-0.5	-0.4	0.0	0.0	0.0	0.0
Change in liquid funds	-13.2	-7.4	-2.0	0.4	-0.8	3.0	2.3
Effects of exchange-rate changes on cash	0.0	-0.1	-0.1	0.1	0.0	0.0	0.0
Cash and cash equivalent at end of period	15.3	7.7	5.6	6.1	5.3	8.2	10.6

Financial Ratios

	2008	2009	2010	2011	2012e	2013e	2014e
Cash Flow							
Free Cash Flow	-1.1	0.0	1.8	2.3	2.2	3.0	2.3
Free Cash Flow / Sales	-10.2 %	0.2 %	12.4 %	16.9 %	15.9 %	22.0 %	18.0 %
Free Cash Flow Potential	-1.7	0.8	-2.5	0.3	1.6	2.3	2.0
Free Cash Flow / Sales	-10.2 %	0.2 %	12.4 %	16.9 %	15.9 %	22.0 %	18.0 %
Free Cash Flow / Net Profit	-52.5 %	7.8 %	-21.2 %	-56.4 %	349.7 %	178.0 %	161.9 %
Interest Received / Avg. Cash	4.3 %	3.4 %	3.3 %	1.4 %	1.4 %	1.2 %	0.9 %
Interest Paid / Avg. Debt	2.9 %	5.9 %	6.5 %	5.7 %	6.2 %	0.0 %	0.0 %
Management of Funds							
Investment ratio	37.1 %	21.9 %	22.2 %	20.5 %	22.4 %	22.7 %	23.5 %
Maint. Capex / Sales	26.2 %	21.2 %	22.3 %	21.4 %	21.2 %	22.2 %	23.1 %
Capex / Dep	367.9 %	107.0 %	35.8 %	46.2 %	95.5 %	96.8 %	100.2 %
Avg. Working Capital / Sales	15.7 %	16.9 %	25.0 %	27.1 %	22.3 %	16.7 %	13.1 %
Trade Debtors / Trade Creditors	225.9 %	376.6 %	390.2 %	378.4 %	292.3 %	220.0 %	200.0 %
Inventory Turnover	2.4 x	3.5 x	8.0 x	2.8 x	5.5 x	5.4 x	5.2 x
Receivables collection period (days)	79	111	131	118	101	89	79
Payables payment period (days)	1,032	891	697	599	866	1,014	983
Cash conversion cycle (Days)	-846	-757	-635	-424	-781	-930	-897

CAPEX and Cash Flow
in EUR m**Free Cash Flow Generation****Working Capital**

Source: Warburg Research

Source: Warburg Research

Source: Warburg Research

LEGAL DISCLAIMER

This research report was prepared by the Warburg Research GmbH, a subsidiary of the M.M.Warburg & CO KGaA and is passed on by the M.M.Warburg & CO KGaA. It contains selected information and does not purport to be complete. The report is based on publicly available information and data ("the information") believed to be accurate and complete. Warburg Research GmbH neither does examine the information to be accurate and complete, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these analyses concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this research report, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this document. Provided a research report is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO KGaA and Warburg Research GmbH is limited to typical, expectable damages. This research report does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this report are subject to change without notice. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO § 34B OF THE GERMAN SECURITIES TRADING ACT AND FINANV

The valuation underlying the rating of the company analysed in this report is based on generally accepted and widely used methods of fundamental valuation, such as the DCF model, Free Cash Flow Value Potential, peer group comparison and – where applicable – a sum-of-the-parts model.

M.M.Warburg & CO KGaA and Warburg Research GmbH have set up internal organisational and administrative arrangements to prevent and avoid possible conflicts of interest and, where applicable, to disclose them.

Valuations, ratings and price targets for the companies analysed by Warburg Research GmbH are subject to constant reviews and may therefore change, if any of the fundamental factors underlying these items do change.

All share prices given in this equity analysis are closing prices on the date given in the analysis, except where stated otherwise.

Neither Warburg Research GmbH's analysts nor M.M.Warburg & CO KGaA's analysts do receive any payments directly or indirectly from any investment banking activity of M.M.Warburg Bank or an affiliated company.

M.M.Warburg & CO KGaA and Warburg Research GmbH are under supervision of the BaFin – German Federal Financial Supervisory Authority.

SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.

Section 34b of the German Securities Trading Act in combination with the FinAnV requires an enterprise preparing a securities analysis to point out possible conflicts of interest with respect to the company that is the subject of the analysis. A conflict of interest is assumed, in particular, when the enterprise preparing the analysis ...

- 1- ... or companies affiliated with this enterprise **holds 5%** or more of the share capital of the analysed company
- 2- ... or companies affiliated with this enterprise was a member in a **consortium** which acquired the shares of the analysed company within the last twelve months
- 3- ... or companies affiliated with this enterprise **manages** the **securities** of the analysed company on the basis of an existing contract
- 4- ... or companies affiliated with this enterprise over the previous 12 months has been providing **investment banking services** for the analysed company for which a compensation has been or will be paid
- 5- ... effected an **agreement** with the analysed company **for the preparation of the financial analysis**
- 6- ... or companies affiliated with this enterprise **regularly trade** in shares or derivatives of the analysed company
- 7- ... or the analyst responsible for this company has **other important financial interests** in relation to the analysed company such as e.g. the performance of mandates for the analysed company

This report has been made accessible to the company analysed.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
MeVis Medical Solutions	3, 4, 5, 6, 7	http://www.mmwarburg.com/disclaimer/disclaimer_en/DE000A0LBFE4.htm

INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given price target in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.
“-“	Rating suspended:	The available information currently does not permit an evaluation of the company.

WARBURG RESEARCH GMBH – RESEARCH UNIVERSE BY RATING


Rating	Number of stocks	% of Universe
Buy	110	57
Hold	68	35
Sell	11	6
Rating suspended	3	2
Total	192	100

WARBURG RESEARCH GMBH – ANALYSED RESEARCH UNIVERSE BY RATING ...

... Looking only at companies for which a disclosure according to § 34b of the Germany Securities Trading Act and the FinAnV has to be made.

Rating	Number of stocks	% of Universe
Buy	98	60
Hold	56	35
Sell	6	4
Rating suspended	2	1
Total	162	100

PRICE AND RATING HISTORY MEVIS MEDICAL SOLUTIONS AS OF 16.11.2012



The chart has markings if Warburg Research GmbH changed its rating in the last 12 months. Every marking represents the date and closing price on the day of the rating change.

RESEARCH

Christian Bruns Head of Research	+49 40 309537-253 cbruns@warburg-research.com
Christian Cohrs Engineering, Logistics	+49 40 309537-175 ccohrs@warburg-research.com
Felix Ellmann Software, IT	+49 40 309537-120 fellmann@warburg-research.com
Jörg Philipp Frey Retail, Consumer Goods	+49 40 309537-258 jfrey@warburg-research.com
Ulrich Huwald Health Care, Pharma	+49 40 309537-255 uhuwald@warburg-research.com
Thilo Kleibauer Retail, Consumer Goods	+49 40 309537-257 tkleibauer@warburg-research.com
Torsten Klingner Real Estate	+49 40 309537-260 tklingner@warburg-research.com
Eggert Kuls Engineering	+49 40 309537-256 ekuls@warburg-research.com
Frank Laser Construction, Industrials	+49 40 309537-235 flaser@warburg-research.com
Andreas Pläsier Banks, Financial Services	+49 40 309537-246 aplaesier@warburg-research.com
Malte Rätther Technology, Telco, Internet	+49 40 309537-185 mraether@warburg-research.com

Henner Rüscheimer Head of Research	+49 40 309537-270 hruescheimer@warburg-research.com
Roland Rapelius Engineering, Logistics	+49 40 309537-220 rrapelius@warburg-research.com
Jochen Reichert Telco, Internet, Media	+49 40 309537-130 jreichert@warburg-research.com
Christopher Rodler Utilities	+49 40 309537-290 crodler@warburg-research.com
Malte Schaumann Technology	+49 40 309537-170 mschaumann@warburg-research.com
Susanne Schwartz Telco, Internet, Media	+49 40 309537-155 sschwartz@warburg-research.com
Oliver Schwarz Chemicals	+49 40 309537-250 oschwarz@warburg-research.com
Marc-René Tonn Automobiles, Car Suppliers	+49 40 309537-259 mtonn@warburg-research.com
Björn Voss Steel, Car Suppliers	+49 40 309537-254 bvoss@warburg-research.com
Andreas Wolf Software, IT	+49 40 309537-140 awolf@warburg-research.com
Stephan Wulf Utilities	+49 40 309537-150 swulf@warburg-research.com

SALES

Holger Nass Head of Equity Sales, USA	+49 40 3282-2669 hnass@mmwarburg.com
Klaus Schilling Dep. Head of Equity Sales, GER	+49 40 3282-2664 kschilling@mmwarburg.com
Christian Alisch Scandinavia, Spain	+49 40 3282-2667 calisch@mmwarburg.com
Robert Conredel Germany	+49 40 3282-2633 rconredel@mmwarburg.com
Matthias Fritsch United Kingdom	+49 40 3282-2696 mfritsch@mmwarburg.com
Marie-Therese Grübner France	+49 40 3282-2630 mgruebner@mmwarburg.com
Michael Kriszun United Kingdom	+49 40 3282-2695 mkriszun@mmwarburg.com
Marc Niemann Germany	+49 40 3282-2660 mniemann@mmwarburg.com
Dirk Rosenfelder Austria, Switzerland	+49 40 3282-2692 drosenfelder@mmwarburg.com
Julian Straube Small & Mid Caps	+49 40 3282-2666 jstraube@mmwarburg.com
Philipp Stumpfegger Australia, United Kingdom	+49 40 3282-2635 pstumpfegger@mmwarburg.com

SALES TRADING

Oliver Merckel Head of Sales Trading	+49 40 3282-2634 omerckel@mmwarburg.com
Gudrun Bolsen Sales Trading	+49 40 3282-2679 gbolsen@mmwarburg.com
Bastian Quast Sales Trading	+49 40 3282-2701 bquast@mmwarburg.com
Patrick Schepelmann Sales Trading	+49 40 3282-2700 pschepelmann@mmwarburg.com
Thekla Struve Sales Trading	+49 40 3282-2668 tstruve@mmwarburg.com
Jörg Treptow Sales Trading	+49 40 3262-2658 jtreptow@mmwarburg.com

Support

Katharina Bruns Roadshow/Marketing	+49 40 3282-2694 kbruns@mmwarburg.com
--	--

MACRO RESEARCH

Carsten Klude Macro Research	+49 40 3282-2572 cklude@mmwarburg.com
Matthias Thiel Macro Research	+49 40 3282-2401 mthiel@mmwarburg.com
Dr. Christian Jasperneite Investment Strategy	+49 40 3282-2439 cjasperneite@mmwarburg.com

Our research can be found under:

Warburg Research	research.mmwarburg.com/en/index.html	Thomson	www.thomson.com
Bloomberg	MMWA GO	Reuters	www.knowledge.reuters.com
FactSet	www.factset.com	Capital IQ	www.capitaliq.com

For access please contact:

Andrea Carstensen Sales Assistance	+49 40 3282-2632 acarstensen@mmwarburg.com	Kerstin Muthig Sales Assistance	+49 40 3282-2703 kmuthig@mmwarburg.com
--	---	---	---